

DIPARTIMENTO ONCO-EMATOLOGICO e di MALATTIE INFETTIVE (DOEMI)
DIRETTORE DR GIORGIO GARDINI

UNITA' OPERATIVA	EMATOLOGIA
-------------------------	-------------------

DIRETTORE	LUIGI GUGLIOTTA
REFERENTE Innovazione e Ricerca	BARBARA GAMBERI

Principali studi in corso:	
LA, LMC:	GIMEMA
LLC, MM:	GIMEMA, GISL
TRAPIANTO:	GITMO, EBMT
*MPD	GIMEMA, RIT, Consortium NIH
* LINFOMI:	IIL, GISL, IELSG,EORTC-GELA, Transatlantico
*PTI:	GIMEMA, REGIONE
*INFEZIONI:	GIMEMA, REGIONE
*Principal Investigator: nazionale (RIT, EXELS, Linfomi Anziani) o regionali (MPD, PTI, INFEZIONI)	

Studi in programmazione:
PTI: Anti-D, Rituximab
MM: Vertebroplastica (spontaneo)
INFEZIONI: spontanei regionali
RICERCA REGIONALE 2007-2009:
Basi Molecolari e Terapia Mirata delle Emolinfopatie Maligne-Costituzione di un network regionale (BO+RE,MO, PR,PR,PC,FE, RA, RN)
MPD/WHO/BOM subprogetto (RE+RA+BO, MO, PR, PC, FE, RN)
Trapianto/Immunodeficienza (Mo+RE, FE, BO)
PET e Linfoma di Hodgkin (MO+RE)

Principali collaborazioni scientifiche e clinico-assistenziali.
ASMN: DOEMI, Radiologia, Laboratorio,.....
Reggio Emilia.: Registro Tumori, RER
Bologna: S. Orsola (Ematologia, Medicina TrASFusionale, Microbiologia, Ginecologia), Rizzoli
Modena: Policlinico (Ematologia , GISL)
Milano: Policlinico (MPD)
Pavia: Policlinico (PTT,MDS,MPD)
Roma: Università La Sapienza (LA, LLC)
Colonia: MPD/BOM
Rotterdam: MPD/WHO
Barcellona: MPD/Registro
Londra: MPD/Studio EXELS
Houston: Linfomi, TMO

Finanziamenti per la ricerca (facoltativi gli importi):

Registro Italiano Trombocitemia (GIMEMA) 50.000 €/anno

Linfomi (Fondazione Maramotti) 120.000 €/anno

MPD/WHO/BOM: Progetto Regione-Università. ? € 40.000

ASSOCIAZIONI SCIENTIFICHE:

SIE, SIES, GITMO, Siset, EHA, ASH, SIA, EBMT, ADMO, ADISCO, IBMDR

GIMEMA, (LMC, LA, MM, LLC, INFEZIONI, PIASTRINOPENIE E ANEMIE)

IIL, GISL, IELSGC

Pubblicazioni (Medline) individuali o accorpate per U. O

(In grassetto i nominativi degli autori del DOEMI)

1: de Fabritiis P, Spagnoli A, Di Bartolomeo P, Locasciulli A, Cudillo L, Milone G, Busca A, Picardi A, Scime R, **Bonini A**, Cupelli L, Chiusolo P, Olivieri A, Santarone S, Poidomani M, Fallani S, Novelli A, Majolino I.

Efficacy of Caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection.

Bone Marrow Transplant. 2007 May 28; [Epub ahead of print]

2: Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, **Merli F**, Orsucci L, Liberati M, Vallisa D, Brugiattelli M; On behalf of the Italian Lymphoma Study Group (GISL). Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.

Cancer. 2007 Jul 1;110(1):121-8.

3: Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, Di Raimondo F, Volpe E, Ronconi S, Cangini D, Narni F, Carubelli A, **Masini L**, Catalano L, Fiacchini M, de Vivo A, Gozzetti A, Lazzaro A, Tura S, Baccarani M. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.

J Clin Oncol. 2007 Jun 10;25(17):2434-41. Epub 2007 May 7.

4: Sacchi S, Pozzi S, Marcheselli L, Bari A, Luminari S, Angrilli F, **Merli F**, Vallisa D, Baldini L, Brugiattelli M; Italian Lymphoma Study Group. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.

Cancer. 2007 May 15;109(10):2077-82.

5: Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, **Gugliotta L**, Bosi A, Barbui T. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia.

Blood. 2007 Mar 22; [Epub ahead of print]

6: Maffei R, Marasca R, Martinelli S, Castelli I, Santachiara R, Morandi E, Zucchini P, Fontana M, Giacobbi F, Silingardi P, Bonacorsi G, Temperani P, **Masini L**, Colacci AM, Serra R, Torelli G. Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status.

Leukemia. 2007 Jun;21(6):1312-5. Epub 2007 Mar 15. No abstract available.

7: Merli F, Bertini M, Luminari S, Mozzana R, Botto B, Liberati AM, Baldini L, Cabras G, Di Vito F, Orsucci L, Naglieri E, Polimeno G, Marcheselli L, Pennese E, Vitolo U, Federico M, Gallo E. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma.
Leuk Lymphoma. 2007 Feb;48(2):367-73.

8: Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Brogna C, Cuoghi A, Dini D, Di Tonno P, Leonardi G, Pianezze G, Pitini V, Polimeno G, Ponchio L, **Masini L**, Musso M, Spriano M, Pollastri G; Gruppo Italiano Studio Linfomi.

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

Leuk Lymphoma. 2007 Jan;48(1):56-64.

9: Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, **Ilariucci F**, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ. Temozolomide as salvage treatment in primary brain lymphomas.

Br J Cancer. 2007 Mar 26;96(6):864-7. Epub 2007 Feb 27.

10: Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E, Carreras E, Saiz A, Lowenberg B, te Boekhorst PA, Gualandio F, Openshaw H, Longo G, Pagliai F, Massacesi L, Deconink E, Ouyang J, Nagore FJ, Besalduch J, Lisukov IA, **Bonini A**, Merelli E, Slavino S, Gratwohl A, Passweg J, Tyndall A, Steck AJ, Andolina M, Capobianco M, Martin JL, Lugaresi A, Meucci G, Saez RA, Clark RE, Fernandez MN, Fouillard L, Herstenstein B, Koza V, Cocco E, Baumann H, Mancardi GL; Autoimmune Diseases Working Party of EBMT. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.
Mult Scler. 2006 Dec;12(6):814-23.

11: Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, **Gugliotta L**, Harrison C, Hasselbalch H, Lengfelder E, Reilly JT, Michiels JJ, Barbui T. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.

Leukemia. 2007 Feb;21(2):277-80. Epub 2006 Nov 16.

12: Malagola M, Damiani D, Martinelli G, Michelutti A, Cesana B, Vivo AD, Piccaluga PP, Ottaviani E, Candoni A, Geromin A, Tiribelli M, Fanin R, Testoni N, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, **Gugliotta L**, **Bonini A**, Visani G, Skert C, Bergonzi C, Roccaro AM, Fili C, Baccarani M, Russo D. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.

Br J Haematol. 2007 Jan;136(1):87-95.

13: Ricci D, Luciano R, Baranello G, Veredice C, Cesarini L, Bianco F, Pane M, Gallini F, Vasco G, Savarese I, Zuppa AA, **Masini L**, Di Rocco C, Romagnoli C, Guzzetta F, Mercuri E. Visual development in infants with prenatal post-haemorrhagic ventricular dilatation.

Arch Dis Child Fetal Neonatal Ed. 2007 Jul;92(4):F255-8. Epub 2006 Dec 1.

14: Scamardella F, Maconi M, Albertazzi L, **Gamberi B**, **Gugliotta L**, Brini M. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.

Lab Hematol. 2006;12(4):187-92.

- 15:** Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, **Gugliotta L**, Vianelli N, Avvisati G, Rodeghiero F, Amendola A, Baronci C, Carboni C, Quattrin S, Fioritoni G, D'Alfonso G, Mandelli F, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. *Blood*. 2007 Feb 15;109(4):1401-7. Epub 2006 Oct 31.
- 16:** Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, **Bonini A**, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. *Haematologica*. 2006 Aug;91(8):1068-75.
- 17:** Pipitone N, **Masini L**, Salvarani C. A case of arthritis and vasculitis associated with the refractory anemia with excess of blasts syndrome resistant to glucocorticoid treatment that responded favorably to TNF-alpha blockade. *Clin Exp Rheumatol*. 2006 Mar-Apr;24(2 Suppl 41):S31-4. No abstract available.
- 18:** Gironi M, Saresella M, Ceresa L, Calvo M, Ferrante P, **Merli F**, Nemni R. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab. *Haematologica*. 2006 Jun;91(6 Suppl):ECR17. No abstract available.
- 19:** Ferreri AJ, Dell'Oro S, Foppoli M, Bernardi M, Brandes AA, Tosoni A, Montanari M, Balzarotti M, Spina M, **Ilariucci F**, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Ponzoni M, Picozzi P, Caligaris Cappio F, Reni M. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. *Neurology*. 2006 May 9;66(9):1435-8.
- 20:** Massari M, **Masini L**. Relationships among injuries treated in an emergency department that are caused by different kinds of animals: epidemiological features. *Eur J Emerg Med*. 2006 Jun;13(3):160-4.
- 21** Calzari MG, Vinceti M, **Avanzini P**, Rodolfi R, Serra L, Luberto F, **Tieghi A**. [Sensitivity and accuracy of health databases in determining incidence of lymphoid malignancies in an Italian population] *Ann Ig*. 2006 Mar-Apr;18(2):127-36. Italian.
- 22:** Gallamini A, Rigacci L, **Merli F**, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. *Haematologica*. 2006 Apr;91(4):475-81.
- 23:** Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortelazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, **Merli F**, Federico M, Franco V, Iannitto E; Integragruppo Italiano Linfomi. Splenic marginal zone lymphoma: a prognostic model for clinical use. *Blood*. 2006 Jun 15;107(12):4643-9. Epub 2006 Feb 21.

24: Federico M, Luminari S, Gobbi PG, Sacchi S, Di Renzo N, Lombardo M, **Merli F**, Baldini L, Stelitano C, Partesotti G, Polimeno G, Montanini A, Mammi C, Brugiatelli M. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.

Eur J Haematol. 2006 Mar;76(3):217-29.

25: Gobbi PG, Broglio C, Valentino F, Mammi C, Lombardo M, **Merli F**, Luminari S, Polimeno G, Riezzo A, Lambelet P, Rovati A, Corazza GR, Federico M; Gruppo Italiano Studio Linfomi. The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL).

Ann Oncol. 2006 Apr;17(4):676-82. Epub 2006 Jan 30.

26: Tosi P, **Gamberi B**, Giuliani N. Biology and treatment of multiple myeloma.

Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):81-6. Review.

27: Morabito F, Stelitano C, Luminari S, Mammi C, Marcheselli L, Callea V, Gentile M, Polimeno G, **Merli F**, Molica S, Gobbi P, Angrilli F, Brugiatelli M, Federico M. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL).

Bone Marrow Transplant. 2006 Feb;37(3):283-8.

28: Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, **Bonini A, Avanzini P, Gugliotta L**, Visani G, Fanin R, Baccarani M. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.

Br J Haematol. 2005 Oct;131(2):172-9. Erratum in: Br J Haematol. 2006 Mar;132(6):804.

29: Gobbi PG, Levis A, Chisesi T, Broglio C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, **Merli F**, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

J Clin Oncol. 2005 Dec 20;23(36):9198-207. Epub 2005 Sep 19.

30: Baldini L, Goldaniga M, Guffanti A, Broglio C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, **Ilariucci F**, Luminari S, Morel P, Merlini G, Gobbi P. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol. 2005 Jul 20;23(21):4662-8.

31: Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, **Gugliotta L**, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T; ECLAP Investigators. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.

Blood. 2005 Apr 1;105(7):2664-70. Epub 2004 Dec 7.

32: Vannucchi AM, Grossi A, Pancrazzi A, Antonioli E, Guglielmelli P, Balestri F, Biscardi M, Bulgarelli S, Longo G, Graziano C, **Gugliotta L**, Bosi A. PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia.

Br J Haematol. 2004 Oct;127(2):214-9.

33: Ferreri AJ, Campo E, Seymour JF, Willemze R, **Ilariucci F**, Ambrosetti A, Zucca E, Rossi G, Lopez-Guillermo A, Pavlovsky MA, Geerts ML, Candoni A, Lestani M, Asioli S, Milani M, Piris MA, Pileri S, Facchetti F, Cavalli F, Ponzoni M; International Extranodal Lymphoma Study Group (IELSG). Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'.

Br J Haematol. 2004 Oct;127(2):173-83. Review.

34: Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, Lazzaro A, Orsucci L, **Ilariucci F**, Sacchi S, Vitolo U, Federico M. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linfomi.

Cancer. 2004 Oct 1;101(7):1601-8.

35: Gobbi PG, Brogna C, Di Giulio G, Mantelli M, Anselmo P, **Merli F**, Zinzani PL, Rossi G, Callea V, Iannitto E, Paulli M, Garioni L, Ascari E. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma.

Cancer. 2004 Oct 15;101(8):1824-34.

36: **Merli F**, Bertini M, Luminari S, Mozzana R, Berte R, Trottini M, Stelitano C, Botto B, Pizzuti M, Quintana G, De Paoli A, Federico M; Intergruppo Italiano Linfomi. Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.

Haematologica. 2004 Aug;89(8):973-8.

37: Ferreri AJ, Campo E, Ambrosetti A, **Ilariucci F**, Seymour JF, Willemze R, Arrigoni G, Rossi G, Lopez-Guillermo A, Berti E, Eriksson M, Federico M, Cortelazzo S, Govi S, Frungillo N, Dell'Oro S, Lestani M, Asioli S, Pedrinis E, Ungari M, Motta T, Rossi R, Artusi T, Iuzzolino P, Zucca E, Cavalli F, Ponzoni M.

Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma.

Ann Oncol. 2004 Aug;15(8):1215-21.

38: Tenedini E, Fagioli ME, Vianelli N, Tazzari PL, Ricci F, Tagliafico E, Ricci P, **Gugliotta L**, Martinelli G, Tura S, Baccarani M, Ferrari S, Catani L. Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells.

Blood. 2004 Nov 15;104(10):3126-35. Epub 2004 Jul 22.

39: Pagano L, Fianchi L, Caramatti C, D'Antonio D, Melillo L, Caira M, **Masini L**, Todeschini G, Girmenia C, Martino B, Cinieri S, Martino P, Del Favero A; Gruppo Italiano Malattie EMatologiche dell'Adulto Infection Program. Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection.

Haematologica. 2004 Jul;89(7):852-6.

40: Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Isidori A, **Bonini A**, **Gugliotta L**, Luppi M, Morselli M, Sparaventi G, Visani G, Baccarani M. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas.

Leuk Lymphoma. 2004 Sep;45(9):1791-5.

41: Vezzani G, Cavazza A, Rossi G, Pasquinelli G, **Avanzini P**, Asioli S, Piana S, Chilosi M. [Pulmonary hyaline-granuloma. Clinicopathologic study of 2 cases, with some original ultrastructural observations and review of the literature]. *Pathologica*. 2004 Feb;96(1):23-8. Review. Italian.

42: Barbuli T, Barosi G, Grossi A, **Gugliotta L**, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Haematologica. 2004 Feb;89(2):215-32. Review.

43: Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory JL, **Ilariucci F**, Volpe A, Bordessoule D, Grossi A, Le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

J Clin Oncol. 2004 Feb 1;22(3):424-31.

Altre informazioni